Evaluación clínica y de la calidad de vida relacionada con la salud en pacientes con dolor torácico no cardiaco

Ortiz-Garrido, O.; Ortiz-Olvera, Nayeli X.; González-Martínez, M.A.; Morán, Segundo; Vargas-López, Guillermo; Dehesa-Violante, Margarita; León, Ana Gloria Vázquez de

doi:10.1016/j.rgmx.2015.03.005

Cited by 14 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rates of GAD and PD are substantially higher in this population than in those in the general population [14, 15], and this is an important public health issue because such patients have impairment of function and quality of life that is greater than those with confirmed heart disease [16]. Furthermore, the repeated utilization of healthcare services by patients with non-cardiac chest pain leads to a substantial financial burden, with the annual cost of such patients’ evaluations measured in the billions [17].…”

Section: Anxiety In Patients With Cardiovascular Diseasementioning

confidence: 99%

Anxiety Disorders and Cardiovascular Disease

Celano

Daunis

Lokko

et al. 2016

Curr Psychiatry Rep

280

173

View full text Add to dashboard Cite

Anxiety and its associated disorders are common in patients with cardiovascular disease and may significantly influence cardiac health. Anxiety disorders are associated with the onset and progression of cardiac disease, and in many instances have been linked to adverse cardiovascular outcomes, including mortality. Both physiologic (autonomic dysfunction, inflammation, endothelial dysfunction, changes in platelet aggregation) and health behavior mechanisms may help to explain the relationships between anxiety disorders and cardiovascular disease. Given the associations between anxiety disorders and poor cardiac health, the timely and accurate identification and treatment of these conditions is of the utmost importance. Fortunately, pharmacologic and psychotherapeutic interventions for the management of anxiety disorders are generally safe and effective. Further study is needed to determine whether interventions to treat anxiety disorders ultimately impact both psychiatric and cardiovascular health.

show abstract

Section: Anxiety In Patients With Cardiovascular Diseasementioning

confidence: 99%

Anxiety Disorders and Cardiovascular Disease

Celano

Daunis

Lokko

et al. 2016

Curr Psychiatry Rep

280

173

View full text Add to dashboard Cite

show abstract

“…12 Several factors contribute to this low QOL, including social withdrawal, avoidance of activities that can elicit or exacerbate symptomatology, and the presence of co-morbid psychiatric conditions such as anxiety and depression. Many patients with NCCP also seek further cardiac assessment, despite diagnostic reassurance.…”

Section: Introductionmentioning

confidence: 99%

Non-cardiac Chest Pain: A Review for the Consultation-Liaison Psychiatrist

et al. 2017

View full text Add to dashboard Cite

Background Patients presenting with chest pain to general practice or emergency providers represent a unique challenge, as the differential is broad and varies widely in acuity. Importantly, most cases of chest pain in both acute and general practice settings are ultimately found to be non-cardiac in origin, and a substantial proportion of patients experiencing non-cardiac chest pain (NCCP) suffer significant disability. In light of emerging evidence that mental health providers can serve a key role in the care of patients with NCCP, knowledge of the differential diagnosis, psychiatric co-morbidities, and therapeutic techniques for NCCP would be of great use to both consultation-liaison (C-L) psychiatrists and other mental health providers. Methods We reviewed prior published work on (1) the appropriate medical workup of the acute presentation of chest pain, (2) the relevant medical and psychiatric differential diagnosis for chest pain determined to be non-cardiac in origin, (3) the management of related conditions in psychosomatic medicine, and (4) management strategies for patients with NCCP. Results We identified key differential diagnostic and therapeutic considerations for psychosomatic medicine providers in 3 different clinical contexts: acute care in the emergency department, inpatient C-L psychiatry, and outpatient C-L psychiatry. We also identified several gaps in the literature surrounding the short-term and long-term management of NCCP in patients with psychiatric etiologies or co-morbid psychiatric conditions. Conclusions Though some approaches to the care of patients with NCCP have been developed, more work is needed to determine the most effective management techniques for this unique and high-morbidity population.

show abstract

Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis

et al. 2021

View full text Add to dashboard Cite

A meta‐analysis was performed to examine therapeutic effects of Silexan on somatic symptoms, including insomnia/fatigue, and physical health in patients with anxiety disorders. Five randomized, placebo‐controlled trials were included in this analysis: The efficacy of Silexan (80 mg/day) was investigated in patients with subthreshold anxiety disorders (three trials) and in patients with generalized anxiety disorder (two trials). Silexan was superior to placebo in terms of the mean change from baseline in the Hamilton Anxiety Rating Scale (HAMA) subscore somatic anxiety at week 10 with a standardized mean difference of −0.31 [95% Cl: −0.52 to −0.10, p = .004]. Treatment effects of silexan on somatic anxiety were independent of gender and age. Statistically significant differences were also shown for single HAMA items somatic muscular, cardiovascular, respiratory, and genitourinary symptoms, indicating clinical relevance with small to medium effects of Silexan. Similar clinically meaningful effects of Silexan on SF‐36 physical health, including reduced bodily pain and improved general health, and on insomnia complaints and fatigue, were demonstrated. In this meta‐analysis including all placebo‐controlled clinical trials in patients with anxiety disorders to date, statistically significant and clinically meaningful advantages of Silexan over placebo treatment were found in improving somatic symptoms and physical health.

show abstract

Evaluación clínica y de la calidad de vida relacionada con la salud en pacientes con dolor torácico no cardiaco

Abstract: In our population, patients with NCCP show deterioration in HR-QoL regardless of the aetiology, frequency, and accompanying symptoms.

Cited by 14 publications

References 34 publications

Anxiety Disorders and Cardiovascular Disease

Anxiety Disorders and Cardiovascular Disease

Non-cardiac Chest Pain: A Review for the Consultation-Liaison Psychiatrist

Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis

Contact Info

Product

Resources

About